GI Bleeding on Oral Anticoagulants in AF Foremost a Cancer Red Flag GI Bleeding on Oral Anticoagulants in AF Foremost a Cancer Red Flag
An observational study'is a wake-up call for us to not let any kind of bleed in the GI tract go without a more detailed investigation for potential cancer,'says an expert observer.Medscape Medical News (Source: Medscape Hematology-Oncology Headlines)
Source: Medscape Hematology-Oncology Headlines - February 15, 2020 Category: Cancer & Oncology Tags: Cardiology News Source Type: news

Bright idea in dentist's office leads to innovative smoking cessation project
Results from this study recently published online in Addiction found primary care physicians providing smokers with a free, two week starter kit of nicotine replacement therapy (NRT) increased quit attempts While sitting in the dentist's office, Hollings Cancer Center researcher Matthew Carpenter, Ph.D., of the Medical University of South Carolina, had a bright idea. As he received his goody bag with dental hygiene products, he wondered why not conduct a study and have primary care providers do the same thing for their patients who use tobacco. The bags would contain educational material, free lozenges and tobacco cessati...
Source: Dental Technology Blog - February 12, 2020 Category: Dentistry Source Type: news

Absent p53, oral cancers recruit and reprogram nerves to fuel tumor growth
(University of Texas M. D. Anderson Cancer Center) Loss of an important tumor-suppressing gene allows head and neck cancer to spin off signals to nearby nerves, changing their function and recruiting them to the tumor, where they fuel growth and cancer progress. (Source: EurekAlert! - Cancer)
Source: EurekAlert! - Cancer - February 12, 2020 Category: Cancer & Oncology Source Type: news

Foot-and-mouth-disease 'could help treat pancreatic CANCER'
A protein from the foot-and-mouth disease virus, which causes mouth blisters and a fever in animals, was developed into a drug to target pancreatic cancer by Queen Mary University. (Source: the Mail online | Health)
Source: the Mail online | Health - February 12, 2020 Category: Consumer Health News Source Type: news

BrainCool AB completes recruitment in trial for FDA clearance of oral mucositis treatment
(King + Company) BrainCool AB, a world leader in medical cooling, has completed patient recruitment for testing of the Intra-Oral Cooling Device Cooral to Eliminate Oral Mucositis, one of the severest side effects of chemotherapy and radiation cancer treatments, and is on track with its De Novo 510(k) process for Market Registration in the U.S. (Source: EurekAlert! - Medicine and Health)
Source: EurekAlert! - Medicine and Health - February 11, 2020 Category: International Medicine & Public Health Source Type: news

Foot-and-mouth-disease virus could help target the deadliest cancer
(Pancreatic Cancer Research Fund) The foot-and-mouth-disease virus is helping scientists to tackle a common cancer with the worst survival rate -- pancreatic cancer. (Source: EurekAlert! - Cancer)
Source: EurekAlert! - Cancer - February 11, 2020 Category: Cancer & Oncology Source Type: news

Janssen Announces Submission to U.S. FDA for New DARZALEX ® (Daratumumab)-Based Combination Regimen for Patients with Relapsed/Refractory Multiple Myeloma
RARITAN, NJ, February 10, 2020 – The Janssen Pharmaceutical Companies of Johnson & Johnson announced today the submission of a supplemental Biologics License Application (sBLA) to the U.S. Food and Drug Administration (FDA) seeking approval of DARZALEX® (daratumumab) in combination with Kyprolis® (carfilzomib) and dexamethasone (DKd) for relapsed/refractory multiple myeloma. The sBLA is supported by results from the Phase 3 CANDOR study, which compared treatment with DKd to carfilzomib and dexamethasone (Kd) in patients with multiple myeloma who relapsed after one to three prior lines of therapy. “W...
Source: Johnson and Johnson - February 10, 2020 Category: Pharmaceuticals Tags: Innovation Source Type: news

GI Bleeding in OAC-Treated A-Fib Patients Indicates CRC Risk
FRIDAY, Feb. 7, 2020 -- Lower-gastrointestinal (GI) bleeding is associated with high risks for colorectal cancer in patients with atrial fibrillation treated with oral anticoagulation (OAC) therapy, according to a study published online Feb. 6 in... (Source: Drugs.com - Pharma News)
Source: Drugs.com - Pharma News - February 7, 2020 Category: Pharmaceuticals Source Type: news

Roche to present new data on Tecentriq in combination with Avastin that shows improvement in overall survival for Chinese patients with the most common form of liver cancer
Basel, 7 February 2020 - Roche (SIX: RO, ROG; OTCQX: RHHBY) today announced that additional data will be presented from a cohort of Chinese patients in the Phase III IMbrave150 study that evaluated Tecentriq ® (atezolizumab) in combination with Avastin® (bevacizumab) as a treatment for people with unresectable hepatocellular carcinoma (HCC) who have not received prior systemic therapy. Data from 194 Chinese patients who took part in the IMbrave150 study were consistent with the global results, that showed a statistically significant and clinically meaningful improvement in overall survival (OS) and progression-free...
Source: Roche Investor Update - February 7, 2020 Category: Pharmaceuticals Source Type: news

Researchers Dose First Patient in Pivotal Study of Duvelisib
The study is evaluating the oral inhibitor for patients with relapsed or refractory follicular  lymphoma. (Source: CancerNetwork)
Source: CancerNetwork - February 7, 2020 Category: Cancer & Oncology Authors: Hannah Slater Source Type: news

Botanical drug is shown to help patients with head and neck cancers
In a UCLA-led phase I clinical trial, a new plant-based drug called APG-157 showed signs of helping patients fight oral and oropharyngeal cancers. These cancers are located in the head and the neck. APG-157 is made up of multiple compounds produced by plants, including curcumin. UCLA Jonsson Comprehensive Cancer Center researchers found that treatment with this botanical drug resulted in (Source: World Pharma News)
Source: World Pharma News - February 6, 2020 Category: Pharmaceuticals Tags: Featured Research Research and Development Source Type: news

Botanical drug is shown to help patients with head and neck cancers
(University of California - Los Angeles Health Sciences) In a UCLA-led phase I clinical trial, a new plant-based drug called APG-157 showed signs of helping patients fight oral and oropharyngeal cancers. These cancers are located in the head and the neck. (Source: EurekAlert! - Medicine and Health)
Source: EurekAlert! - Medicine and Health - February 6, 2020 Category: International Medicine & Public Health Source Type: news

Botanical drug is shown to help patients with head and neck cancers
In this study, UCLA researchers found that when APG-157 is taken through oral mucosal absorption, patients have high levels of curcumin circulating in their blood and absorbed by cancer tissues.METHODUCLA researchers conducted the study of APG-157 comparing 12 people who had oral and oropharyngeal cancer with a control group of 13 people who did not have cancer. The reason both the people with cancer and without cancer were part of the study was to show that the drug was not toxic to either people with cancer or those without cancer.The medication was given each hour for three hours and was delivered as a lozenge that slow...
Source: UCLA Newsroom: Health Sciences - February 6, 2020 Category: Universities & Medical Training Source Type: news

Clostridium perfringens enterotoxin induces claudin-4 to activate YAP in oral squamous cell
(Impact Journals LLC) Oncotarget Volume 11, Issue 4: Treatment of human oral squamous cell carcinoma cell lines HSC3 and HSC4 with Clostridium perfringens enterotoxin, induced CLDN4 nuclear translocation to enhance epithelial-mesenchymal transition, stemness, cell proliferation, and invasive ability. (Source: EurekAlert! - Cancer)
Source: EurekAlert! - Cancer - February 4, 2020 Category: Cancer & Oncology Source Type: news

Janssen to Highlight Depth of Solid Tumor Portfolio at ASCO GU
RARITAN, N.J., February 3, 2020 – The Janssen Pharmaceutical Companies of Johnson & Johnson announced today multiple data presentations from a robust solid tumor portfolio that will be featured at the American Society of Clinical Oncology Genitourinary (ASCO GU) Cancers Symposium, taking place February 13-15 in San Francisco. Company-sponsored data presentations will include clinical results for ERLEADA® (apalutamide) and niraparib in prostate cancer; and BALVERSA™ (erdafitinib) in bladder cancer. “We are committed to improving outcomes in patients with prostate and bladder cancer where high unmet...
Source: Johnson and Johnson - February 3, 2020 Category: Pharmaceuticals Tags: Innovation Source Type: news

Therapeutic targeting of preleukemia cells in a mouse model of NPM1 mutant acute myeloid leukemia
The initiating mutations that contribute to cancer development are sometimes present in premalignant cells. Whether therapies targeting these mutations can eradicate premalignant cells is unclear. Acute myeloid leukemia (AML) is an attractive system for investigating the effect of preventative treatment because this disease is often preceded by a premalignant state (clonal hematopoiesis or myelodysplastic syndrome). In Npm1c/Dnmt3a mutant knock-in mice, a model of AML development, leukemia is preceded by a period of extended myeloid progenitor cell proliferation and self-renewal. We found that this self-renewal can be reve...
Source: ScienceNOW - January 30, 2020 Category: Science Authors: Uckelmann, H. J., Kim, S. M., Wong, E. M., Hatton, C., Giovinazzo, H., Gadrey, J. Y., Krivtsov, A. V., Rücker, F. G., Döhner, K., McGeehan, G. M., Levine, R. L., Bullinger, L., Vassiliou, G. S., Armstrong, S. A. Tags: Medicine, Diseases reports Source Type: news

Oral Vinorelbine With Endocrine Therapy for Breast Cancer Oral Vinorelbine With Endocrine Therapy for Breast Cancer
Is the combination of oral metronomic vinorelbine plus letrozole safe and effective for ER+ breast cancer?Breast Cancer Research (Source: Medscape Today Headlines)
Source: Medscape Today Headlines - January 28, 2020 Category: Consumer Health News Tags: Hematology-Oncology Journal Article Source Type: news

Oral health, gut microbiome and cancer prevention: Poor dental hygiene is associated with 75 percent INCREASED RISK of liver cancer
(Natural News) As it turns out, regularly brushing and flossing your teeth protects more than just your smile. In a new study published in the United European Gastrenterology Journal, researchers from Queen’s University Belfast said poor oral health may be linked to an increased risk for a specific type of liver cancer. According to Haydée WT Jordão, a researcher at... (Source: NaturalNews.com)
Source: NaturalNews.com - January 28, 2020 Category: Consumer Health News Source Type: news

Roche submits supplemental Biologics License Application to the FDA for Tecentriq in combination with Avastin for the most common form of liver cancer
      ·Application is being reviewed under FDA ’s Real-Time Oncology Review pilot programmeBasel, 27 January 2020 – Roche (SIX: RO, ROG; OTCQX: RHHBY) today announced the completion of a supplemental Biologics License Application (sBLA) submission to the US Food and Drug Administration (FDA) for Tecentriq® (atezolizumab) in combination with Avastin® (bevacizumab), for the treatment of people with unresectab le hepatocellular carcinoma (HCC) who have not received prior systemic therapy. The FDA is reviewing the application under the Real-Time Oncology Review pilot programme, wh...
Source: Roche Investor Update - January 27, 2020 Category: Pharmaceuticals Source Type: news

FDA approves Blueprint's stomach cancer therapy priced at $32,000 per month
The U.S. Food and Drug Administration approved Blueprint Medicines Corp's oral therapy to treat a rare form of cancer that affects the stomach and small intestine, the agency said on Thursday. (Source: Reuters: Health)
Source: Reuters: Health - January 10, 2020 Category: Consumer Health News Tags: healthNews Source Type: news

Oral health, gut microbiome and cancer prevention: Poor dental hygiene is associated with 75 percent INCREASED RISK of liver cancer
(Natural News) As it turns out, regularly brushing and flossing your teeth protects more than just your smile. In a new study published in the United European Gastrenterology Journal, researchers from Queen’s University Belfast said poor oral health may be linked to an increased risk for a specific type of liver cancer. According to Haydée... (Source: NaturalNews.com)
Source: NaturalNews.com - January 9, 2020 Category: Consumer Health News Source Type: news

Breakthroughs in Metastatic Breast Cancer From SABCS 2019 Breakthroughs in Metastatic Breast Cancer From SABCS 2019
In metastatic breast cancer, top news at SABCS 2019 focused on two highly active drugs in HER2+ disease, an oral paclitaxel in TNBC, and evidence for a new standard front-line therapy in HR+ disease.Medscape (Source: Medscape Today Headlines)
Source: Medscape Today Headlines - January 8, 2020 Category: Consumer Health News Tags: None ReCAP Source Type: news

Lilly opens Phase 3 clinical trial in RET-mutant medullary thyroid cancer
Eli Lilly and Company (NYSE: LLY) announced the opening of the LIBRETTO-531 clinical trial [NCT04211337] for selpercatinib, also known as LOXO-292, for treatment-naive RET-mutant medullary thyroid cancer (MTC) patients. This is the second Phase 3 trial to open for selpercatinib, a highly selective and potent, oral investigational new medicine in clinical development for the treatment of patients with cancers that harbor abnormalities in the rearranged during transfection (RET) kinase. (Source: World Pharma News)
Source: World Pharma News - January 3, 2020 Category: Pharmaceuticals Tags: Featured Eli Lilly and Company Business and Industry Source Type: news

Could 1 Dose of HPV Vaccine Be Enough?
First introduced in 2006, the multi-dose human papillomavirus (HPV) vaccine can prevent most cervical and anal cancers among children and young adults exposed to the virus. It can also prevent the majority of both HPV-driven oral and penile cancers. (Source: WebMD Health)
Source: WebMD Health - December 27, 2019 Category: Consumer Health News Source Type: news

Acupuncture May Ease a Common Side Effect of Cancer Treatment, Dry Mouth
FRIDAY, Dec. 27, 2019 -- Dry mouth can be a troubling side effect of radiation therapy, but acupuncture may ease its symptoms, a new study suggests. Of 339 patients getting radiation for head and neck cancer in the United States and China, those... (Source: Drugs.com - Daily MedNews)
Source: Drugs.com - Daily MedNews - December 27, 2019 Category: General Medicine Source Type: news

New test offers personalised treatment for child brain tumours
Measuring lipid and glutamine levels predicts how fast a tumour will grow Related items fromOnMedica Sentinel node biopsy first to check spread of oral cancer NHS annual cancer checks top two million Cancer research funding boost following death of Tessa Jowell Nanoparticle drug delivery system could help fight brain cancer Men ’s dementia risk higher after androgen deprivation therapy (Source: OnMedica Latest News)
Source: OnMedica Latest News - December 27, 2019 Category: UK Health Source Type: news

Head and neck cancer symptoms: One symptom of the deadly disease you should never ignore
HEAD and neck cancers affect the mouth, nose and throat and is a deadly disease that is becoming more and more prevalent. There is an easily missed sign of the condition that one should look out for. What is it? (Source: Daily Express - Health)
Source: Daily Express - Health - December 20, 2019 Category: Consumer Health News Source Type: news

Top UCLA news stories of 2019
UCLA began observing its 100th birthday this year and delivered new  advances in research, health care, the arts, community service and teaching. These are some of the top stories from UCLA Newsroom in 2019 — those which made news and engaged the community of Bruins and beyond.UCLA Newsroom will resume publishing on Jan. 2, 2020. For more, be sure toperuse the archives and to followUCLA Newsroom on Twitter. UCLA turns 100UCLA ArchiveUCLA from overhead in the 1930s.Founders of UCLA would marvel at their creationIn just 100 years, UCLA has grown into a respected center of learning, research and health ca...
Source: UCLA Newsroom: Health Sciences - December 19, 2019 Category: Universities & Medical Training Source Type: news

Court Delays Oral Arguments In Glyphosate Cancer Appeal Due To Volume Of Briefs
SAN FRANCISCO - An appellate panel in California on Dec. 6 issued an order indicating that it will attempt to schedule oral argument in Monsanto Co.'s appeal of a $78,506,418.35 glyphosate cancer verdict in March or April 2020, despite the fact that the plaintiff has shown a compelling need to have the appeal resolved as soon as possible and the briefing in the case has been completed (DeWayne Johnson v. Monsanto Company, Nos. A155940 and A156706, Calif. App., 1st Dist.). (Source: LexisNexis® Mealey's™ Emerging Toxic Torts Legal News)
Source: LexisNexis® Mealey's™ Emerging Toxic Torts Legal News - December 18, 2019 Category: Medical Law Source Type: news

Pfizer wins FDA approval for 'first and only' oral treatment for prostate cancer drug
Pfizer Inc. confirmed that the U.S. Food and Drug Administration (FDA) has approved a supplemental new drug application to treat prostate cancer. The New York-based pharma giant, which opened Tuesday morning at $39.46 a share, created the new cancer drug with Japan-based Astellas Pharma Inc. The treatment, Xtandi, helps patients with metastatic hormone-sensitive prostate cancer (mCSPC). This type of prostate cancer spreads to other parts o f the body. In 2019, it is estimated that just over 40,000… (Source: bizjournals.com Health Care:Biotechnology headlines)
Source: bizjournals.com Health Care:Biotechnology headlines - December 17, 2019 Category: Biotechnology Authors: Anthony Noto Source Type: news

Novel Agent Boosts Adjuvant Therapy for High-Risk Breast Cancer Novel Agent Boosts Adjuvant Therapy for High-Risk Breast Cancer
For postoperative breast cancer patients with a high risk of recurrence, the oral fluoropyrimidine-based drug S-1 could boost benefits of standard adjuvant treatment.Medscape Medical News (Source: Medscape Medical News Headlines)
Source: Medscape Medical News Headlines - December 16, 2019 Category: Consumer Health News Tags: Hematology-Oncology News Source Type: news

Paclitaxel Pill Tops IV Response, but Needs 9-Hour Fast Paclitaxel Pill Tops IV Response, but Needs 9-Hour Fast
Among women with metastatic breast cancer, use of an investigational oral form of paclitaxel yielded a higher overall response rate than the IV form, but administration was unique and time-consuming.Medscape Medical News (Source: Medscape Radiology Headlines)
Source: Medscape Radiology Headlines - December 14, 2019 Category: Radiology Tags: Hematology-Oncology News Source Type: news

Paclitaxel Now a Pill, but Needs 9 Hours of Fasting to Take Paclitaxel Now a Pill, but Needs 9 Hours of Fasting to Take
Among women with metastatic breast cancer, use of an investigational oral form of paclitaxel yielded a higher overall response rate than the IV form, but administration was unique and time-consuming.Medscape Medical News (Source: Medscape Medical News Headlines)
Source: Medscape Medical News Headlines - December 13, 2019 Category: Consumer Health News Tags: Hematology-Oncology News Source Type: news

Paclitaxel Pill Tops IV Form, but Needs 9-Hour Fast Paclitaxel Pill Tops IV Form, but Needs 9-Hour Fast
Among women with metastatic breast cancer, use of an investigational oral form of paclitaxel yielded a higher overall response rate than the IV form, but administration was unique and time-consuming.Medscape Medical News (Source: Medscape Hematology-Oncology Headlines)
Source: Medscape Hematology-Oncology Headlines - December 13, 2019 Category: Cancer & Oncology Tags: Hematology-Oncology News Source Type: news

Saliva test shows promise for earlier and easier detection of mouth and throat cancer
(Elsevier) Unfortunately, cancers that occur in the back of the mouth and upper throat are often not diagnosed until they become advanced. A report in The Journal of Molecular Diagnostics describes the use of acoustofluidics, a new non-invasive method that analyzes saliva for the presence of human papilloma virus (HPV)-16, the pathogenic strain associated with oropharyngeal cancers (OPCs). This novel technique detected OPC in whole saliva in 40 percent of patients tested and 80% of confirmed OPC patients. (Source: EurekAlert! - Medicine and Health)
Source: EurekAlert! - Medicine and Health - December 13, 2019 Category: International Medicine & Public Health Source Type: news

New Standard Likely for Some Metastatic HER2 Breast Cancer New Standard Likely for Some Metastatic HER2 Breast Cancer
The investigational oral therapy tucatinib, when added to standard trastuzumab and capecitabine, resulted in a"clinically meaningful" lower risk of disease progression or death compared with placeboMedscape Medical News (Source: Medscape Hematology-Oncology Headlines)
Source: Medscape Hematology-Oncology Headlines - December 11, 2019 Category: Cancer & Oncology Tags: Hematology-Oncology News Source Type: news

Addition of S-1 to Endocrine Therapy Postoperatively Improves Survival in HR+, HER2- Breast Cancer
Adjuvant therapy with S-1, an oral fluoropyrimidine-based drug, plus endocrine therapy postoperatively significantly increased invasive disease-free survival (IDFS) in patients with HR-positive, HER2-negative breast cancer. (Source: CancerNetwork)
Source: CancerNetwork - December 11, 2019 Category: Cancer & Oncology Authors: Kristie L. Kahl Source Type: news

Even a Little Alcohol May Raise Cancer Risk
Associations between drinking and cancer were particularly strong for cancers of the mouth, throat, stomach and colon. (Source: NYT Health)
Source: NYT Health - December 9, 2019 Category: Consumer Health News Authors: Nicholas Bakalar Tags: Alcoholic Beverages Cancer Source Type: news

Acupuncture reduces radiation-induced dry mouth for cancer patients
(University of Texas M. D. Anderson Cancer Center) After receiving acupuncture treatment three days a week during the course of radiation treatment, head and neck cancer patients experienced less dry mouth, according to study results from researchers at The University of Texas MD Anderson Cancer Center. (Source: EurekAlert! - Cancer)
Source: EurekAlert! - Cancer - December 6, 2019 Category: Cancer & Oncology Source Type: news

Call for More HPV-Related Primary Prevention Call for More HPV-Related Primary Prevention
A lack of clinician recommendation is adding to low rates of HPV immunization, report specialists, who say it's time for dentists to educate patients and families about HPV-related oral cancers.Medscape Medical News (Source: Medscape Medical News Headlines)
Source: Medscape Medical News Headlines - December 4, 2019 Category: Consumer Health News Tags: Dental & Oral Health News Source Type: news

NOTCH1 signaling in oral squamous cell carcinoma via a TEL2/SERPINE1 axis
In this study, the research team investigated NOTCH1 mutations in keratinocyte lines derived from OSCC biopsies that had been subjected to whole exome sequencing. (Source: EurekAlert! - Cancer)
Source: EurekAlert! - Cancer - December 4, 2019 Category: Cancer & Oncology Source Type: news

Tackling the Complications From Oral Cancer and Treatment Tackling the Complications From Oral Cancer and Treatment
Difficulties with oral health can continue long after any evidence of cancer is apparent, and it's important that health teams remain vigilant monitoring for recurrence.Medscape Medical News (Source: Medscape Medical News Headlines)
Source: Medscape Medical News Headlines - December 3, 2019 Category: Consumer Health News Tags: Dental & Oral Health News Source Type: news

HEALTH NOTES: Half of Britons say they've never heard of HPV 
Research by the Oral Health Foundation showed that two-thirds of Britons don't realise that HPV is contracted through sexual contact. HPV can trigger cancer in the mouth, throat and cervix. (Source: the Mail online | Health)
Source: the Mail online | Health - November 16, 2019 Category: Consumer Health News Source Type: news

Two thirds of Britons unable to spot mouth cancer signs, poll suggests
Public awareness needs to increase to make sure the disease is picked up early and curb rise in cases, says Oral Health Foundation Related items fromOnMedica NHS must improve access to screening to save lives Third of emergency cancer presenters never saw GP Smartphone apps miss a third of melanomas Public urged to know what pancreatic cancer symptoms to look out for Parents urged to take toddlers for dental check (Source: OnMedica Latest News)
Source: OnMedica Latest News - November 15, 2019 Category: UK Health Source Type: news

Attention Vegetable Haters: It Could Be In Your Genes
By Sandee LaMotte, CNN (CNN) — If certain vegetables have always made you gag, you may be more than a picky eater. Instead, you might be what scientists call a “super-taster:” a person with a genetic predisposition to taste food differently. Unfortunately, being a super-taster doesn’t make everything taste better. In fact, it can do the opposite. Super-tasters are extremely sensitive to bitterness, a common characteristic of many dark green, leafy veggies such as broccoli, cauliflower, cabbage and Brussels sprouts, to name a few. “The person who has that genetic propensity gets more of the sul...
Source: WBZ-TV - Breaking News, Weather and Sports for Boston, Worcester and New Hampshire - November 12, 2019 Category: Consumer Health News Authors: Health – CBS Boston Tags: Health News CNN Source Type: news

Mount Sinai researcher's examine the metabolic effects of an oral blood cancer drug
(The Mount Sinai Hospital / Mount Sinai School of Medicine) Recent study found that an effective blood cancer treatment was associated with weight gain, obesity, and increased systolic blood pressure. (Source: EurekAlert! - Medicine and Health)
Source: EurekAlert! - Medicine and Health - November 12, 2019 Category: International Medicine & Public Health Source Type: news

Mount Sinai researchers examine the metabolic effects of an oral blood cancer drug
(The Mount Sinai Hospital / Mount Sinai School of Medicine) Recent study found that an effective blood cancer treatment was associated with weight gain, obesity, and increased systolic blood pressure. (Source: EurekAlert! - Cancer)
Source: EurekAlert! - Cancer - November 12, 2019 Category: Cancer & Oncology Source Type: news

Mount Sinai Researcher ’s Examine the Metabolic Effects of an Oral...
Recent study found that an effective blood cancer treatment was associated with weight gain, obesity, and increased systolic blood pressure(PRWeb November 12, 2019)Read the full story at https://www.prweb.com/releases/mount_sinai_researchers_examine_the_metabolic_effects_of_an_oral_blood_cancer_drug/prweb16714864.htm (Source: PRWeb: Medical Pharmaceuticals)
Source: PRWeb: Medical Pharmaceuticals - November 12, 2019 Category: Pharmaceuticals Source Type: news

Mouth cancer symptoms: This sign on your tongue could signal the deadly disease
MOUTH cancer rate has increased by over 50 percent in the past decade. It is the world ’s eleventh most common cancer, with around 640,000 cases being diagnosed globally each year. Spotting a certain sign on your tongue could signal the disease. What is it? (Source: Daily Express - Health)
Source: Daily Express - Health - November 8, 2019 Category: Consumer Health News Source Type: news

Scientists determine: Oral contraceptive use INCREASES breast cancer risk by 50 percent
(Natural News) There are lots of reasons women might not want to take birth control pills. They can cause all sorts of unpleasant side effects, especially moodiness and weight gain. However, there’s an even better reason to avoid oral contraceptives that you might not even be aware of: They raise your breast cancer risk by... (Source: NaturalNews.com)
Source: NaturalNews.com - November 5, 2019 Category: Consumer Health News Source Type: news